- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04625673
OsciPulse Device for the Prevention of VTE
Phase 2, Randomized Study of the Tolerability and Safety of the OsciPulse Device for the Prevention of VTE
This is a Phase 2 safety and tolerability trial that will take place in two parts. Part one of the trial will determine the tolerability of the OsciPulse device on healthy subjects who wear the device for up to three hours. Healthy volunteers will answer questionnaires and may undergo an ultrasound test at the end of their participation in the trial.
Part two of the trial will determine the safety and tolerability of the OsciPulse device on subjects admitted to Penn Presbyterian Medical Center. Eligible subjects will be enrolled for 6 hours. In the first 3 hours, subjects will wear the standard of care intermittent pneumatic compression device or the OsciPulse device. In the second 3 hours, the subject's device will be switched and subjects will wear the alternate device not used in the first 3 hours. Subjects will answer questionnaires and may undergo an ultrasound at the end of the first 3 hours and at the end of the second 3 hours (at hour 6).
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Penn Presbyterian Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Part 1: Adult over the age of 40, generally healthy without a current foot or ankle injury, no history of diagnosed vascular disease including DVT, PE, VTE, post-phlebetic syndrome, or chronic venous insufficiency, mentally alert and understand English proficiently, able to give informed consent
Part 2: Adult over the age of 18, admitted to the at Penn Presbyterian Medical Center, anticipated decreased level of mobility for at least 6 hours as determined by the clinical team in collaboration with study personnel, mentally alert and understand English proficiently, able to give informed consent.
Exclusion Criteria:
Part 1: injury to the lower limbs, skin breaks, abrasion, or irritation in the area of the limb in contact with the OsciPulse device.
Part 2:
Inability or contraindication to applying IPC to both legs such as:
- Evidence of bone fracture in lower extremities
- Burns in the lower extremities, lacerations, ulcers, active skin infection or dermatitis, & ischemic limb in the legs at the site of IPC placement
- Acute ischemia in the lower extremities
- Severe peripheral vascular disease
- Amputated foot or leg on one or two sides
- Compartment syndrome
- Severe lower extremity edema
- Subjects anticipated to require surgical intervention within six (6) hours of admission
- Subjects with history of VTE (DVT or PE)
- Previous vascular surgery
- Pregnancy or within 6 weeks of postpartum period
- Limitation of life support, life expectancy < 7 days or palliative care
- Admitted to an outside hospital more than 24 hours prior to screening
- A head-unit is unavailable for the 6 hours or more
- At the discretion of the attending physician and / or clinical team, the subject's participation in the study is believed not to be in the best interest of the subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A
Group A will wear the OsciPulse device for the first 3 hours then switch to the standard IPC device for the second 3 hours.
|
OsciPulse device and standard IPC device
Other Names:
|
Active Comparator: Group B
Group B will wear the standard IPC device for the first 3 hours then switch to the OsciPulse device for the second 3 hours.
|
OsciPulse device and standard IPC device
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 - Subject's Response to Tolerability Questionnaire
Time Frame: up to 3 hours
|
Tolerability will be measured by subject's response to questionnaires to assess their experience with the device.
This will be measured on a linear 100 mm visual acuity scale measured in millimeters.
Subjects are provided with the scale and asked to make a mark on the line that corresponds to their experience with the device.
The least favorable rating is on the left hand side, the most favorable rating is on the right hand side of the scale.
The mark on the line is measured in millimeters, resulting in least favorable scores having a lower score, and most favorable ratings having a higher score.
|
up to 3 hours
|
Part 1 - Safety Assessment Through Collection of Adverse Events
Time Frame: up to 3 hours
|
Safety will be assessed by collecting & reviewing all adverse events while subject is wearing the device. Subjects will indicate if the device caused 1) no discomfort, 2) mild discomfort, or 3) significant discomfort. To move on to Part 2, all subjects in Part 1 must indicate that there was not "significant discomfort." |
up to 3 hours
|
Part 2 - Subject's Response to Tolerability Questionnaire
Time Frame: 6 hours
|
Tolerability will be measured by subject's response to questionnaires to assess their experience with the device.
This will be measured on a linear 100mm visual acuity scale measured in millimeters.
Subjects are provided with the scale and asked to make a mark on the line that corresponds to their experience with the device.
The minimum (least favorable) rating is on the left hand side and is equal to zero (0), the maximum (most favorable) rating is on the right hand side of the scale and is equal to one hundred (100).
For Comfort, scores range from "very disruptive" (0) to "no effect" (10).
For Disruption, scores range from "very disruptive" (0) to "no effect" (10).
For Noise, scores range from "very loud" (0) to "not noticeable" (10).
For Movement, scores range from "very restrictive" (0) to "no effect" (10).
The mark on the line is measured in millimeters, resulting in minimum (least favorable) scores having a lower score, and maximum (most favorable) ratings having a higher score.
|
6 hours
|
Part 2 - Safety Assessment Through Collection of Adverse Events.
Time Frame: 6 hours
|
Safety will be assessed by collecting all adverse events while the subject is wearing the device.
|
6 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Adam Cuker, MD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 844294
- OSC-VTE-001 (Other Identifier: University of Pennsylvania)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Deep Vein Thrombosis
-
University of OklahomaPfizerCompleted
-
University Medical Center GroningenCompletedSuspected Upper Extremity Deep Vein ThrombosisAustria, Netherlands, Italy, Belgium, Switzerland, Germany, United States
-
National Taiwan University HospitalUnknownUpper Extremity Deep Vein Thrombosis, SecondaryTaiwan
-
University of Missouri-ColumbiaTerminatedDEEP VEIN THROMBOSISUnited States
-
Vetex Medical Ltd.CompletedDeep Vein Thrombosis LegIreland, Germany, Bulgaria, United Kingdom
-
MinaPharm PharmaceuticalsRecruitingProphylaxis of Deep Vein ThrombosisEgypt
-
McMaster UniversityCanadian Institutes of Health Research (CIHR)CompletedSuspected Deep Vein ThrombosisCanada
-
Diakron PharmaceuticalsCompleted
-
UPECLIN HC FM Botucatu UnespCompletedProphylaxis of Deep Vein ThrombosisBrazil
-
BayerRecruitingThrombolysis | Symptomatic Proximal Deep Vein ThrombosisBelgium, France, Italy, Netherlands, Canada, Germany
Clinical Trials on OsciPulse
-
OsciFlex LLCUniversity of PennsylvaniaWithdrawn
-
OsciFlex LLCUniversity of Pennsylvania; National Heart, Lung, and Blood Institute (NHLBI)CompletedVenous Stasis | Venous ThrombosesUnited States